Molecular causes of colon cancer

European Journal of Clinical Investigation

Volumn 32, Issue 6, 2002, Pages 448-457

  Oving, Irma M ^a   Clevers, Hans C ^a  

^a UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

Author keywords

Adenomatous polyposis coli; Axin; Beta catenin; Cancer; Wnt signalling

Indexed keywords

APC PROTEIN; AXIN; BETA CATENIN; BIOCHEMICAL MARKER; WNT PROTEIN;

CANCER; CANCER DIAGNOSIS; CANCER THERAPY; CELL DIVISION; COLON ADENOMA; COLON CARCINOGENESIS; COLON CARCINOMA; COLON MUCOSA; COLON POLYPOSIS; DIAGNOSTIC PROCEDURE; DISEASE ASSOCIATION; DISEASE MARKER; DRUG DESIGN; DRUG TARGETING; EMBRYO DEVELOPMENT; GENE CONTROL; GENE MUTATION; GENE TARGETING; GENETIC ANALYSIS; HUMAN; MALIGNANT TRANSFORMATION; MICROSATELLITE INSTABILITY; MOLECULAR BIOLOGY; NONHUMAN; PREDICTION; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN FUNCTION; REVIEW; SIGNAL TRANSDUCTION; TUMOR SUPPRESSOR GENE;

ADENOMATOUS POLYPOSIS COLI PROTEIN; ALPHA CATENIN; ANIMALS; BETA CATENIN; CARCINOMA; COLONIC NEOPLASMS; CYTOSKELETAL PROTEINS; HUMANS; PROTEINS; PROTO-ONCOGENE PROTEINS; REPRESSOR PROTEINS; SIGNAL TRANSDUCTION; TRANS-ACTIVATORS; WNT PROTEINS; ZEBRAFISH PROTEINS;

EID: 0036997873     PISSN: 00142972     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-2362.2002.01004.x     Document Type: Review

References (104)

1. Mao J, Wang J, Liu B, Pan W, Farr GH, Flynn C et al. Low-density lipoprotein receptor-related protein-5 binds to axin and regulates the canonical wnt signaling pathway. Mol Cell 2001;7:801-9.
2. Tamai K, Semenov M, Kato Y, Spokony R, Liu C, Katsuyama Y et al. LDL-receptor-related proteins in Wnt signal transduction. Nature 2000;407:530-5.
3. Bhanot P, Brink M, Samos CH, Hsieh JC, Wang Y, Macke JP et al. A new member of the frizzled family from Drosophila functions as a Wingless receptor. Nature 1996;382:225-30.
4. Smalley MJ, Sara E, Paterson H, Naylor S, Cook D, Jayatilake H et al. Interaction of axin and Dvl-2 proteins regulates Dvl-2-stimulated TCF-dependent transcription. EMBO J 1999;18:2823-35.
5. Kishida S, Yamamoto H, Hino S, Ikeda S, Kishida M, Kikuchi A. DIX domains of Dvl and axin are necessary for protein interactions and their ability to regulate beta-catenin stability. Mol Cell Biol 1999;19:4414-22.
6. Itoh K, Krupnik VE, Sokol SY. Axis determination in Xenopus involves biochemical interactions of axin, glycogen synthase kinase 3 and beta-catenin. Curr Biol 1998;8:591-4.
7. Rubinfeld B, Albert I, Porfiri E, Fiol C, Munemitsu S, Polakis P. Binding of GSK3beta to the APC-beta-catenin complex and regulation of complex assembly [see comments]. Science 1996;272:1023-6.
8. Hart MJ, de los Santos R, Albert IN, Rubinfeld B, Polakis P. Downregulation of beta-catenin by human Axin and its association with the APC tumor suppressor, beta-catenin and GSK3 beta. Curr Biol 1998;8:573-81.
9. Yost C, Torres M, Miller JR, Huang E, Kimelman D, Moon RT. The axis-inducing activity, stability, and subcellular distribution of beta-catenin is regulated in Xenopus embryos by glycogen synthase kinase 3. Genes Dev 1996;10:1443-54.
10. Yamamoto H, Kishida S, Kishida M, Ikeda S, Takada S, Kikuchi A. Phosphorylation of axin, a Wnt signal negative regulator, by glycogen synthase kinase-3beta regulates its stability. J Biol Chem 1999;274:10681-4.
11. Aberle H, Bauer A, Stappert J, Kispert A, Kemler R. beta-catenin is a target for the ubiquitin-proteasome pathway. EMBO J 1997;16:3797-804.
12. Marikawa Y, Elinson RP. beta-TrCP is a negative regulator of Wnt/beta-catenin signaling pathway and dorsal axis formation in Xenopus embryos. Mech Dev 1998;77:75-80.
13. Behrens J, von Kries JP, Kuhl M, Bruhn L, Wedlich D, Grosschedl R et al. Functional interaction of beta-catenin with the transcription factor LEF-1. Nature 1996;382:638-42.
14. Hart M, Concordet JP, Lassot I, Albert I, del los Santos R, Durand H et al. The F-box protein beta-TrCP associates with phosphorylated beta-catenin and regulates its activity in the cell. Curr Biol 1999;9:207-10.
15. Molenaar M, van de Wetering M, Oosterwegel M, Peterson-Maduro J, Godsave S, Korinek V et al. XTcf-3 transcription factor mediates beta-catenin-induced axis formation in Xenopus embryos. Cell 1996;86:391-9.
16. Roose J, Molenaar M, Peterson J, Hurenkamp J, Brantjes H, Moerer P et al. The Xenopus Wnt effector XTcf-3 interacts with Groucho-related transcriptional repressors. Nature 1998;395:608-12.
17. Brantjes H, Roose J, van de Wetering M, Clevers H. All Tcf HMG box transcription factors interact with Groucho-related co-repressors. Nucleic Acids Res 2001;29:1410-9.
18. Waltzer L, Bienz M.Drosophila CBP represses the transcription factor tcf to antagonize Wingless signaling. Nature 1998;395:521-5.
19. Brannon M, Brown JD, Bates R, Kimelman D, Moon RT. XCtBP is a XTcf-3 co-repressor with roles throughout Xenopus development. Development 1999;126:3159-70.
20. Ishitani T, Ninomiya-Tsuji J, Nagai S, Nishita M, Meneghini M, Barker N et al. The TAK1-NLK-MAPK-related pathway antagonizes signalling between beta- catenin and transcription factor TCF. Nature 1999;399:798-802.
21. He TC, Sparks AB, Rago C, Hermeling H, Zawel L, da Costa LT et al. Identification of c-MYC as a target of the APC pathway [see comments]. Science 1998;281:1509-12.
22. Roose J, Huls G, van Beest M, Moerer P, van der Horn K, Goldschmeding R et al. Synergy between tumor suppressor APC and the beta-catenin-Tcf4 target Tcf1. Science 1999;285:1923-6.
23. Brabletz T, Jung A, Dag S, Hlubek F, Kirchner T. beta-catenin regulates the expression of the matrix metalloproteinase-7 in human colorectal cancer. Am J Pathol 1999;155:1033-8.
24. Crawford HC, Fingleton BM, Rudolph-Owen LA, Goss KJ, Rubinfeld B, Polakis P et al. The metalloproteinase matrilysin is a target of beta-catenin transactivation in intestinal tumors. Oncogene 1999;18:2883-91.
25. Groden J, Thliveris A, Samowitz W, Carlson M, Gelbert L, Albertsen H et al. Identification and characterization of the familial adenomatous polyposis coli gene. Cell 1991;66:589-600.
26. Kinzler KW, Vogelstein B. Lessons from hereditary colorectal cancer. Cell 1996;87:159-70.
27. Rubinfeld B, Souza B, Albert I, Muller O, Chamberlain SH, Masiarz H et al. Association of the APC gene product with beta-catenin. Science 1993;262:1731-4.
28. Su LK, Vogelstein B, Kinzler KW. Association of the APC tumor suppressor protein with catenins. Science 1993;262:1734-7.
29. Seeling JM, Miller JR, Gil R, Moon RT, White R, Virshup DM. Regulation of beta-catenin signaling by the B56 subunit of protein phosphatase 2A. Science 1999;283:2089-91.
30. Hsu W, Zeng L, Costantini F. Identification of a domain of Axin that binds to the serine/threonine protein phosphatase 2A and a self-binding domain. J Biol Chem 1999;274:3439-45.
31. Kawasaki Y, Senda T, Ishidate T, Koyama R, Morishita T, Iwayama Y et al. Asef, a link between the tumor suppressor APC and G-protein signaling. Science 2000;289:1194-7.
32. Rubinfeld B, Albert I, Porfiri E, Munemitsu S, Polakis P. Loss of beta-catenin regulation by the APC tumor suppressor protein correlates with loss of structure due to common somatic mutations of the gene. Cancer Res 1997;57:4624-30.
33. Bienz M, Clevers H. Linking colorectal cancer to Wnt signaling. Cell 2000;103:311-20.
34. van Es JH, Giles RH, Clevers HC. The many faces of the tumor suppressor gene APC. Exp Cell Res 2001;264:126-34.
35. Hinoi T, Yamamoto H, Kishida M, Takada S, Kishida S, Kikuchi A. Complex formation of adenomatous polyposis coli gene product and axin facilitates glycogen synthase kinase-3beta-dependent phosphorylation of beta-catenin and down-regulates beta-catenin [In Process Citation]. J Biol Chem 2000;275:34399-406.
36. Zhang F, White RL, Neufeld KL. Phosphorylation near nuclear localization signal regulates nuclear import of adenomatous polyposis coli protein. Proc Natl Acad Sci USA 2000;97:12577-82.
37. Rosin-Arbesfeld R, Townsley F, Bienz M. The APC tumour suppressor has a nuclear export function. Nature 2000;406:1009-12.
38. Henderson BR. Nuclear-cytoplasmic shuttling of APC regulates beta-catenin subcellular localization and turnover. Nat Cell Biol 2000;2:653-60.
39. Neufeld KL, Zhang F, Cullen BR, White RL. APC-mediated downregulation of beta-catenin activity involves nuclear sequestration and nuclear export. EMBO Report 2000;1:519-23.
40. Erdmann KS, Kuhlmann J, Lessmann V, Herrmann L, Eulenburg V, Muller O et al. The Adenomatous Polyposis Coli-protein (APC) interacts with the protein tyrosine phosphatase PTP-BL via an alternatively spliced PDZ domain. Oncogene 2000;19:3894-901.
41. Matsumine A, Ogai A, Senda T, Okumara N, Satoh K, Baeg GH et al. Binding of APC to the human homolog of the Drosophila discs large tumor suppressor protein. Science 1996;272:1020-3.
42. Senda T, Iino S, Matsushita K, Matsumine A, Kobayashi S, Akiyama T. Localization of the adenomatous polyposis coli tumour suppressor protein in the mouse central nervous system. Neuroscience 1998;83:857-66.
43. Kaplan KB, Burds AA, Swedlow JR, Bekir SS, Sorger PK, Nathke IS. A role for the Adenomatous Polyposis Coli protein in chromosome segregation. Nat Cell Biol 2001;3:429-32.
44. Su LK, Burrell M, Hill DE, Gyuris J, Brent R, Wiltshire R et al. APC binds to the novel protein EB1. Cancer Res 1995;55:2972-7.
45. Tirnauer JS, Bierer BE. EB1 proteins regulate microtubule dynamics, cell polarity, and chromosome stability. J Cell Biol 2000;149:761-6.
46. Fodde R, Kuipers J, Rosenberg C, Smits R, Kielman M, Gaspar C et al. Mutations in the APC tumour suppressor gene cause chromosomal instability. Nat Cell Biol 2001;3:433-8.
47. Nagafuchi A, Takeichi M. Transmembrane control of cadherin-mediated cell adhesion: a 94 kDa protein functionally associated with a specific region of the cytoplasmic domain of E-cadherin. Cell Regul 1989;1:37-44.
48. Ozawa M, Baribault H, Kemler R. The cytoplasmic domain of the cell adhesion molecule uvomorulin associates with three independent proteins structurally related in different species. EMBO J 1989;8:1711-7.
49. Orsulic S, Peifer M. An in vivo structure-function study of armadillo, the beta-catenin homologue, reveals both separate and overlapping regions of the protein required for cell adhesion and for wingless signaling. J Cell Biol 1996;134:1283-300.
50. Cox RT, Kirkpatrick C, Peifer M. Armadillo is required for adherens junction assembly, cell polarity, and morphogenesis during Drosophila embryogenesis. J Cell Biol 1996;134:133-48.
51. Polakis P. Wnt signaling and cancer. Genes Dev 2000;14:1837-51.
52. van de Wetering M, Cavallo R, Dooijes D, van Beest M, van Es J, Loureiro J et al. Armadillo coactivates transcription driven by the product of the Drosophila segment polarity gene dTCF. Cell 1997;88:789-99.
53. Hsu SC, Galceran J, Grosschedl R. Modulation of transcriptional regulation by LEF-1 in response to Wnt-1 signaling and association with beta-catenin. Mol Cell Biol 1998;18:4807-18.
54. Hecht A, Litterst CM, Huber O, Kemler R. Functional characterization of multiple transactivating elements in beta-catenin, some of which interact with the TATA-binding protein in vitro. J Biol Chem 1999;274:18017-25.
55. Hecht A, Vleminckx K, Stemmler MP, van Roy F, Kemler R. The p300/CBP acetyltransferases function as transcriptional coactivators of beta-catenin in vertebrates. EMBO J 2000;19:1839-50.
56. Takemaru KI, Moon RT. The transcriptional coactivator CBP interacts with beta-catenin to activate gene expression. J Cell Biol 2000;149:249-54.
57. Barker N, Hurlstone A, Musisi H, Miles A, Bienz M, Clevers H. The chromatin remodelling factor Brg-1 interacts with beta-catenin to promote target gene activation. EMBO J 2001;20:4935-43.
58. Behrens J, Jerchow BA, Wurtele M, Grimm J, Asbrand C, Wirtz R et al. Functional interaction of an axin homolog, conductin, with beta-catenin, APC, and GSK3beta. Science 1998;280:596-9.
59. Yamamoto H, Kishida S, Uochi T, Ikeda S, Koyama S, Asashima M et al. Axil, a member of the Axin family, interacts with both glycogen synthase kinase 3beta and beta-catenin and inhibits axis formation of Xenopus embryos. Mol Cell Biol 1998;18:2867-75.
60. Ikeda S, Kishida S, Yamamoto H, Murai H, Koyama S, Kikuchi A. Axin, a negative regulator of the Wnt signaling pathway, forms a complex with GSK-3beta and beta-catenin and promotes GSK-3beta-dependent phosphorylation of beta-catenin. EMBO J 1998;17:1371-84.
61. Kishida S, Yamamoto H, Ikeda S, Kishida M, Sakamoto I, Koyama S et al. Axin, a negative regulator of the wnt signaling pathway, directly interacts with adenomatous polyposis coli and regulates the stabilization of beta-catenin. J Biol Chem 1998;273:10823-6.
62. Sakanaka C, Williams LT. Functional domains of axin. Importance of the C terminus as an oligomerization domain. J Biol Chem 1999;274:14090-3.
63. Willert K, Shibamoto S, Nusse R. Wnt-induced dephosphorylation of axin releases beta-catenin from the axin complex. Genes Dev 1999;13:1768-73.
64. Morin PJ, Sparks AB, Korinek V, Barker N, Clevers H, Vogelstein B et al. Activation of beta-catenin-Tcf signaling in colon cancer by mutations in beta-catenin or APC [see comments]. Science 1997;275:1787-90.
65. Rubinfeld B, Robbins P, El Gamil M, Albert I, Porfiri E, Polakis P. Stabilization of beta-catenin by genetic defects in melanoma cell lines. Science 1997;275:1790-2.
66. Polakis P. The oncogenic activation of beta-catenin. Curr Opin Genet Dev 1999;9:15-21.
67. Iwao K, Nakamori S, Kameyama M, Imaoka S, Kinoshita M, Fukui T et al. Activation of the beta-catenin gene by interstitial deletions involving exon 3 in primary colorectal carcinomas without adenomatous polyposis coli mutations. Cancer Res 1998;58:1021-6.
68. Sparks AB, Morin PJ, Vogelstein B, Kinzler KW. Mutational analysis of the APC/beta-catenin/Tcf pathway in colorectal cancer. Cancer Res 1998;58:1130-4.
69. Mirabelli-Primdahl L, Gryfe R, Kim H, Millar A, Luceri C, Dale D et al. Beta-catenin mutations are specific for colorectal carcinomas with microsatellite instability but occur in endometrial carcinomas irrespective of mutator pathway. Cancer Res 1999;59:3346-51.
70. Miyaki M, Iijima T, Kimura J, Yasuno M, Mori T, Hayashi Y et al. Frequent mutation of beta-catenin and APC genes in primary colorectal tumors from patients with hereditary nonpolyposis colorectal cancer. Cancer Res 1999;59:4506-9.
71. Su LK, Kinzler KW, Vogelstein B, Preisinger AC, Moser AR, Luongo C et al. Multiple intestinal neoplasia caused by a mutation in the murine homolog of the APC gene [published erratum appears in Science 1992; 5: 1114]. Science 1992;256:668-70.
72. Kinzler KW, Nilbert MC, Su LK, Vogelstein B, Bryan TM, Levy DB et al. Identification of FAP locus genes from chromosome 5q21. Science 1991;253:661-5.
73. Miyoshi Y, Nagase H, Ando H, Horii A, Ichii S, Nakatsuru S et al. Somatic mutations of the APC gene in colorectal tumors: mutation cluster region in the APC gene. Hum Mol Genet 1992;1:229-33.
74. Munemitsu S, Albert I, Souza B, Rubinfeld B, Polakis P. Regulation of intracellular beta-catenin levels by the adenomatous polyposis coli (APC) tumor-suppressor protein. Proc Natl Acad Sci USA 1995;92:3046-50.
75. Shih IM, Yu J, He TC, Vogelstein B, Kinzler KW. The beta-catenin binding domain of adenomatous polyposis coli is sufficient for tumor suppression. Cancer Res 2000;60:1671-6.
76. Nagase H, Nakamura Y. Mutations of the APC (adenomatous polyposis coli) gene. Hum Mutat 1993;2:425-34.
77. Korinek V, Barker N, Moerer P, van Donselaar E, Huls G, Peters PJ et al. Depletion of epithelial stem-cell compartments in the small intestine of mice lacking Tcf-4. Nat Genet 1998;19:379-83.
78. Harada N, Tamai Y, Ishikawa T, Sauer B, Takaku K, Oshima M et al. Intestinal polyposis in mice with a dominant stable mutation of the beta-catenin gene. EMBO J 1999;18:5931-42.
79. Pellman D. Cancer: a CINtillating new job for the APC tumor suppressor. Science 2001;291:2555-6.
80. Liu W, Dong X, Mai M, Seelan RS, Taniguchi K, Krishnadath KK et al. Mutations in AXIN2 cause colorectal cancer with defective mismatch repair by activating beta-catenin/TCF signalling [In Process Citation]. Nat Genet 2000;26:146-7.
81. Satoh S, Daigo Y, Furukawa Y, Kato T, Miwa N, Nishiwaki T et al. AXIN1 mutations in hepatocellular carcinomas, and growth suppression in cancer cells by virus-mediated transfer of AXIN1. Nat Genet 2000;24:245-50.
82. Webster MT, Rozycka M, Sara E, Davis E, Smalley M, Young N et al. Sequence variants of the axin gene in breast, colon, and other cancers: an analysis of mutations that interfere with GSK3 binding. Genes Chromosomes Cancer 2000;28:443-53.
83. Smith DR, Myint T, Goh HS. Over-expression of the c-myc proto-oncogene in colorectal carcinoma. Br J Cancer 1993;68:407-13.
84. Imaseki H, Hayashi H, Taira M, Ito Y, Tabata Y, Onoda S et al. Expression of c-myc oncogene in colorectal polyps as a biological marker for monitoring malignant potential. Cancer 1989;64:704-9.
85. Sikora K, Chan S, Evan G, Gabra H, Markham N, Stewart J et al. c-myc oncogene expression in colorectal cancer. Cancer 1987;59:1289-95.
86. Leder P, Battey J, Lenoir G, Moulding C, Murphy W, Potter H et al. Translocations among antibody genes in human cancer. Science 1983;222:765-71.
87. Breckenridge DG, Shore GC. Regulation of apoptosis by E1A and Myc oncoproteins. Crit Rev Eukaryot Gene Expr 2000;10:273-80.
88. Tetsu O, McCormick F. Beta-catenin regulates expression of cyclin D1 in colon carcinoma cells. Nature 1999;398:422-6.
89. Lin SY, Xia W, Wang JC, Kwong KY, Spohn B, Wen Y et al. Beta-catenin, a novel prognostic marker for breast cancer: its roles in cyclin D1 expression and cancer progression. Proc Natl Acad Sci USA 2000;97:4262-6.
90. Bartkova J, Lukas J, Strauss M, Bartek J. The PRAD-1/cyclin D1 oncogene product accumulates aberrantly in a subset of colorectal carcinomas. Int J Cancer 1994;58:568-73.
91. Arber N, Hibshoosh H, Moss SF, Sutter T, Zhang Y, Begg M et al. Increased expression of cyclin D1 is an early event in multistage colorectal carcinogenesis. Gastroenterology 1996;110:669-74.
92. Smalley WE, DuBois RN. Colorectal cancer and nonsteroidal anti-inflammatory drugs. Adv Pharmacol 1997;39:1-20.
93. He TC, Chan TA, Vogelstein B, Kinzler KW. PPARdelta is an APC-regulated target of nonsteroidal anti-inflammatory drugs. Cell 1999;99:335-45.
94. Shiff SJ, Qiao L, Tsai LL, Rigas B. Sulindac sulfide, an aspirin-like compound, inhibits proliferation, causes cell cycle quiescence, and induces apoptosis in HT-29 colon adenocarcinoma cells. J Clin Invest 1995;96:491-503.
95. Piazza GA, Alberts DS, Hixson LJ, Paranka NS, Li H, Finn T et al. Sulindac sulfone inhibits azoxymethane-induced colon carcinogenesis in rats without reducing prostaglandin levels. Cancer Res 1997;57:2909-15.
96. Newell KJ, Witty JP, Rodgers WH, Matrisian LM. Expression and localization of matrix-degrading metalloproteinases during colorectal tumorigenesis. Mol Carcinog 1994;10:199-206.
97. Fingleton BM, Heppner Goss KJ, Crawford HC, Matrisian LM. Matrilysin in early stage intestinal tumorigenesis. APMIS 1999;107:102-10.
98. Takeuchi N, Ichikawa Y, Ishikawa T, Momiyama N, Hasegawa S, Nagashima et al. Matrilysin gene expression in sporadic and familial colorectal adenomas. Mol Carcinog 1997;19:225-9.
99. Korinek V, Barker N, Morin PJ, van Wichen D, de Weger R, Kinzler KW et al. Constitutive transcriptional activation by a beta-catenin-Tcf complex in APC-/- colon carcinoma [see comments]. Science 1997;275:1784-7.
100. Wilson CL, Heppner KJ, Labosky PA, Hogan BL, Matrisian LM. Intestinal tumorigenesis is suppressed in mice lacking the metalloproteinase matrilysin. Proc Natl Acad Sci USA 1997;94:1402-7.
101. Watanabe T, Wu TT, Catalano PJ, Ueki T, Satriano R, Haller DG et al. Molecular predictors of survival after adjuvant chemotherapy for colon cancer. N Engl J Medl 2001;344:1196-206.
102. Gryfe R, Kim H, Hsieh ET, Aronson MD, Holowaty EJ, Bull SB et al. Tumor microsatellite instability and clinical outcome in young patients with colorectal cancer. N Engl J Med 2000;342:69-77.
103. Brunori M, Malerba M, Kashiwazaki H, Iggo R. Replicating adenoviruses that target tumors with constitutive activation of the wnt signaling pathway. J Virol 2001;75:2857-65.
104. Chen RH, McCormick F. Selective targeting to the hyperactive beta-catenin/T-cell factor pathway in colon cancer cells. Cancer Res 2001;61: 4445-9.